

Hiroshi Nomoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7522186/publications.pdf>

Version: 2024-02-01

82
papers

825
citations

643344

15
h-index

651938

25
g-index

84
all docs

84
docs citations

84
times ranked

1364
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | IAPP-induced beta cell stress recapitulates the islet transcriptome in type 2 diabetes. <i>Diabetologia</i> , 2022, 65, 173-187. | 2.9 | 19 |
| 2 | Glucokinase activation leads to an unsustained hypoglycaemic effect with hepatic triglyceride accumulation in db/db mice. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 391-401. | 2.2 | 6 |
| 3 | Impact of low-starch high-fiber pasta on postprandial blood glucose. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 487-493. | 1.1 | 3 |
| 4 | Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?. <i>Endocrine Journal</i> , 2022, 69, 495-509. | 0.7 | 2 |
| 5 | Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-9. | 1.0 | 5 |
| 6 | Lymphocytic panhypophysitis and anti-rabphilin-3A antibody with pulmonary sarcoidosis. <i>Pituitary</i> , 2022, 25, 321. | 1.6 | 2 |
| 7 | Diabetic Chorea. <i>Journal of General Internal Medicine</i> , 2022, , . | 1.3 | 0 |
| 8 | Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study). <i>BMJ Open</i> , 2022, 12, e056885. | 0.8 | 2 |
| 9 | Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function. <i>Scientific Reports</i> , 2022, 12, . | 1.6 | 3 |
| 10 | Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1272-1277. | 1.1 | 28 |
| 11 | Sodium-glucose cotransporter 2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes. <i>Journal of Diabetes Investigation</i> , 2021, 12, 176-183. | 1.1 | 8 |
| 12 | Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycosylated hemoglobin or diabetes treatment. <i>Journal of Diabetes Investigation</i> , 2021, 12, 738-746. | 1.1 | 10 |
| 13 | Combination of alcohol and glucose consumption as a risk to induce reactive hypoglycemia. <i>Journal of Diabetes Investigation</i> , 2021, 12, 651-657. | 1.1 | 6 |
| 14 | Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1395-1399. | 1.1 | 1 |
| 15 | Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The Tj ETQq1 1 0.784314 rgBT / Överlock | 1.2 | 3 |
| 16 | Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia. <i>Endocrine Journal</i> , 2021, 68, 477-484. | 0.7 | 15 |
| 17 | Silent pituitary adenoma and metabolic disorders: obesity, abnormal glucose tolerance, hypertension and dyslipidemia. <i>Endocrine Journal</i> , 2021, 68, 195-200. | 0.7 | 4 |
| 18 | Glucokinase Inactivation Paradoxically Ameliorates Glucose Intolerance by Increasing β -Cell Mass in db/db Mice. <i>Diabetes</i> , 2021, 70, 917-931. | 0.3 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1417-1424. | 1.1 | 2 |
| 20 | Glucokinase is required for high-starch diet-induced β -cell mass expansion in mice. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1545-1554. | 1.1 | 3 |
| 21 | Log-linear relationship between endogenous insulin secretion and glycemic variability in patients with type 2 diabetes on continuous glucose monitoring. <i>Scientific Reports</i> , 2021, 11, 9057. | 1.6 | 7 |
| 22 | The association between hypoglycemia and glycemic variability in elderly patients with type 2 diabetes: a prospective observational study. <i>Diabetology and Metabolic Syndrome</i> , 2021, 13, 37. | 1.2 | 4 |
| 23 | Favorable Effects of Burosumab on Fibroblast Growth Factor 23-Related Osteomalacia: A Case Report. <i>Journal of the Endocrine Society</i> , 2021, 5, A194-A194. | 0.1 | 0 |
| 24 | Neuromedin B Receptor Antagonist Suppresses Pomc Expression in AtT-20 Cells and Human Corticotroph Adenoma Cells. <i>Journal of the Endocrine Society</i> , 2021, 5, A546-A547. | 0.1 | 0 |
| 25 | Dipeptidyl peptidase-4 inhibitor might exacerbate Graves' disease: A multicenter observational case-control study. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1978-1982. | 1.1 | 5 |
| 26 | 7-LB: Lowering of Blood Pressure and Pulse Rate by Switching from DPP-4 Inhibitor to Luseogliflozin in Patients with Type 2 Diabetes and Hypertension: A Multicenter, Prospective, Randomized, Open-Label, Parallel-Group Comparison Trial. <i>Diabetes</i> , 2021, 70, 7-LB. | 0.3 | 0 |
| 27 | 780-P: Improved Mitochondrial Function by Luseogliflozin Prevents Pancreatic Beta-Cell Damage. <i>Diabetes</i> , 2021, 70, . | 0.3 | 0 |
| 28 | Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor. <i>Internal Medicine</i> , 2021, 60, 2375-2383. | 0.3 | 1 |
| 29 | Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study). <i>Diabetes Research and Clinical Practice</i> , 2021, 180, 109069. | 1.1 | 4 |
| 30 | False hypercortisolemia due to abnormal albumin-cortisol binding in a patient with familial dysalbuminemic hyperthyroxinemia. <i>Thyroid</i> , 2021, , . | 2.4 | 0 |
| 31 | Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor. <i>Medicine (United States)</i> , 2021, 100, e27895. | 0.4 | 6 |
| 32 | Activation of the HIF1 α /PFKFB3 stress response pathway in beta cells in type 1 diabetes. <i>Diabetologia</i> , 2020, 63, 149-161. | 2.9 | 49 |
| 33 | Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study). <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 458-462. | 2.2 | 12 |
| 34 | Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study. <i>BMJ Open</i> , 2020, 10, e034883. | 0.8 | 2 |
| 35 | Intrafamilial phenotypic distinction of hypophosphatasia with identical tissue nonspecific alkaline phosphatase gene mutation: a family report. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 903-907. | 1.3 | 2 |
| 36 | 1993-P: Impact of Laparoscopic Sleeve Gastrectomy on Glycemic Control in Japanese Patients with Obesity and Type 2 Diabetes. <i>Diabetes</i> , 2020, 69, 1993-P. | 0.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | MON-483 Familial Dysalbuminemic Hyperthyroxinemia with False Hypercortisolemia. Journal of the Endocrine Society, 2020, 4, . | 0.1 | 0 |
| 38 | 2084-P: Hepatic Fat Accumulation Underlies the Inability of Glucokinase Activator to Achieve a Sustained Hypoglycemic Effect in db/db Mice. Diabetes, 2020, 69, . | 0.3 | 0 |
| 39 | 1145-P: SGLT2 Inhibitors Improve Day-to-Day Glucose Variability in Patients with Type 1 Diabetes. Diabetes, 2020, 69, 1145-P. | 0.3 | 0 |
| 40 | MON-465 Novel Thyroid Hormone β Mutation L266s Causes Atrial Fibrillation & Cerebral Infarction. Journal of the Endocrine Society, 2020, 4, . | 0.1 | 0 |
| 41 | SAT-271 Block and Replace Therapy Successfully Improved Symptoms in Recurrent Cyclic Cushing's Disease. Journal of the Endocrine Society, 2020, 4, . | 0.1 | 0 |
| 42 | SAT-282 Hypothalamic Pituitary Adrenal Axis Hyperactivity in Db/db Mice. Journal of the Endocrine Society, 2020, 4, . | 0.1 | 0 |
| 43 | Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial. Journal of Diabetes Investigation, 2019, 10, 699-705. | 1.1 | 26 |
| 44 | Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea. Journal of Diabetes Investigation, 2019, 10, 367-374. | 1.1 | 15 |
| 45 | IAPP toxicity activates HIF1 α /PFKFB3 signaling delaying β -cell loss at the expense of β -cell function. Nature Communications, 2019, 10, 2679. | 5.8 | 55 |
| 46 | Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice. Metabolism: Clinical and Experimental, 2019, 98, 27-36. | 1.5 | 28 |
| 47 | Identification of sinensetin and nobiletin as major antitrypanosomal factors in a citrus cultivar. Experimental Parasitology, 2019, 200, 24-29. | 0.5 | 16 |
| 48 | Breakdown of Autonomously Functioning Thyroid Nodule Accompanied by Acromegaly After Octreotide Treatment. Frontiers in Endocrinology, 2019, 10, 131. | 1.5 | 4 |
| 49 | Low Grade Islet but Marked Exocrine Pancreas Inflammation in an Adult with Autoimmune Pre-Diabetes. Case Reports in Endocrinology, 2019, 2019, 1-6. | 0.2 | 2 |
| 50 | Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation, 2019, 10, 429-438. | 1.1 | 7 |
| 51 | 2361-PUB: Enhancement of Flattening Glycemic Fluctuation in Patients with Type 2 Diabetes by SGLT2 Inhibitor Combined with DPP-4 Inhibitor. Diabetes, 2019, 68, 2361-PUB. | 0.3 | 0 |
| 52 | 1855-P: Effects of Dapagliflozin and/or Insulin Glargine on Hepatic Steatosis in db/db Mice. Diabetes, 2019, 68, . | 0.3 | 0 |
| 53 | HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors. Journal of Investigative Dermatology, 2018, 138, 1201-1204. | 0.3 | 94 |
| 54 | The role of glucokinase and insulin receptor substrate-2 in the proliferation of pancreatic beta cells induced by short-term high-fat diet feeding in mice. Metabolism: Clinical and Experimental, 2018, 85, 48-58. | 1.5 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetesâ€”Randomized controlled studyâ€”. Endocrine Journal, 2018, 65, 141-150. | 0.7 | 7 |
| 56 | The Effect of Everolimus on Refractory Hypoglycemia in a Patient with Inoperable Metastatic Insulinoma Evaluated by Continuous Glucose Monitoring. Internal Medicine, 2018, 57, 2527-2531. | 0.3 | 1 |
| 57 | Thyrotoxicosis in Graves' Disease with Invasive Laryngeal Cancer. Internal Medicine, 2018, 57, 1495-1496. | 0.3 | 1 |
| 58 | Potential Importance of a Histopathological Analysis in Thyroidal Diseases with High Serum IgG4 Levels. Internal Medicine, 2018, 57, 453-453. | 0.3 | 1 |
| 59 | Two Cases of Transiently Elevated Serum CEA Levels in Severe Hypothyroidism without Goiter. Internal Medicine, 2018, 57, 2523-2526. | 0.3 | 1 |
| 60 | Effect of the sodiumâ€”glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages. Scientific Reports, 2018, 8, 6864. | 1.6 | 22 |
| 61 | Comment on â€œElevation of Serum Carcinoembryonic Antigen Concentration Caused by Everolimus-Induced Lung Injury: A Case Reportâ€”. Annals of Thoracic and Cardiovascular Surgery, 2018, 24, 165-166. | 0.3 | 0 |
| 62 | A case of osteomalacia due to deranged mineral balance caused by saccharated ferric oxide and short-bowel syndrome. Medicine (United States), 2017, 96, e8147. | 0.4 | 5 |
| 63 | A case of frontotemporal dementia with sexual disinhibition controlled by aripiprazole. Psychogeriatrics, 2017, 17, 509-510. | 0.6 | 10 |
| 64 | The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3). Cardiovascular Diabetology, 2017, 16, 125. | 2.7 | 24 |
| 65 | A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin. Diabetology and Metabolic Syndrome, 2017, 9, 54. | 1.2 | 35 |
| 66 | Effects of 50 mg vildagliptin twice daily <i>vs.</i> 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose. Endocrine Journal, 2017, 64, 417-424. | 0.7 | 7 |
| 67 | Factors associated with an inadequate hypoglycemia in the insulin tolerance test in Japanese patients with suspected or proven hypopituitarism. Endocrine Journal, 2017, 64, 387-392. | 0.7 | 1 |
| 68 | Do DPP-4 inhibitors improve endothelial cell function?. , 2017, 01, . | | 1 |
| 69 | Impact of incretin-related agents on endothelial cell function. Clinical Trials in Degenerative Diseases, 2017, . | 0.1 | 1 |
| 70 | A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1). PLoS ONE, 2016, 11, e0164255. | 1.1 | 29 |
| 71 | Usefulness of the octreotide test in Japanese patients for predicting the presence/absence of somatostatin receptor 2 expression in insulinomas. Endocrine Journal, 2016, 63, 135-142. | 0.7 | 8 |
| 72 | Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus. Endocrine Journal, 2016, 63, 53-60. | 0.7 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. <i>Endocrine Journal</i> , 2016, 63, 589-596. | 0.7 | 49 |
| 74 | Serum brain-derived neurotrophic factor levels and personality traits in patients with major depression. <i>BMC Psychiatry</i> , 2015, 15, 33. | 1.1 | 14 |
| 75 | Inhibition of Small Maf Function in Pancreatic β -Cells Improves Glucose Tolerance Through the Enhancement of Insulin Gene Transcription and Insulin Secretion. <i>Endocrinology</i> , 2015, 156, 3570-3580. | 1.4 | 12 |
| 76 | A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2). <i>PLoS ONE</i> , 2015, 10, e0135854. | 1.1 | 40 |
| 77 | The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 311-324. | 0.9 | 6 |
| 78 | Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1785-1795. | 0.9 | 2 |
| 79 | TbGT8 is a bifunctional glycosyltransferase that elaborates N-linked glycans on a protein phosphatase AcP115 and a GPI-anchor modifying glycan in <i>Trypanosoma brucei</i> . <i>Parasitology International</i> , 2014, 63, 513-518. | 0.6 | 11 |
| 80 | Intracellular interaction of newly synthesized nerve growth factor and its receptors. <i>Biochemical and Biophysical Research Communications</i> , 2013, 432, 456-459. | 1.0 | 0 |
| 81 | Ovarian morphology and prevalence of polycystic ovary syndrome in Japanese women with type 1 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2013, 4, 326-329. | 1.1 | 21 |
| 82 | Type 2 Diabetes is a Beta Cell Protein Misfolding Disease. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |